Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.59 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 10/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CALML3 | P27482 | 1/20 | 0.46 |
| ▸ | SDHA | P31040 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13428775 | 1.00 | MAOA (0.59) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL11969026 | 0.90 | MAOA (0.71) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL13428773 | 0.90 | MAOA (0.71) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL11969017 | 0.90 | MAOA (0.54) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL13428757 | 0.87 | MAOA (0.62) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL11969076 | 0.87 | MAOA (0.57) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL13428425 | 0.86 | MAOA (0.58) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL11969035 | 0.85 | MAOA (0.57) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL11969741 | 0.84 | MAOA (0.59) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL11969693 | 0.84 | MAOA (0.58) | MAOACYP2E1MAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242113-B2 | Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-08-14 | — | — | US | disclosed |
| US-8242113-B2 | Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof | LEGOCHEM BIOSCIENCES, INC. (KR) | 2012-08-14 | — | — | US | disclosed |
| US-20110178293-A1 | Novel Oxazolidinone Derivatives with Cyclic Amidoxime or Cyclic Amidrazone and Pharmaceutical Compositions Thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178293-A1 | Novel Oxazolidinone Derivatives with Cyclic Amidoxime or Cyclic Amidrazone and Pharmaceutical Compositions Thereof | LEGOCHEM BIOSCIENCE LTD. (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2010036000-A2 | NOVEL OXAZOLIDINONE DERIVATIVES WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AND PHARMACEUTICAL COMPOSITIONS THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178293-A1 | Novel Oxazolidinone Derivatives with Cyclic Amidoxime or Cyclic Amidrazone and Pharmaceutical Compositions Thereof | PAM, PYCARD, PEPD | MAOA 3476/4885CYP2E1 1772/4885MAOB 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.